HBP vs. MBX, BCT, APS, ATE, RVX, AEZS, TH, ONC, MDNA, and SVA
Should you be buying Helix BioPharma stock or one of its competitors? The main competitors of Helix BioPharma include Microbix Biosystems (MBX), BriaCell Therapeutics (BCT), Aptose Biosciences (APS), Antibe Therapeutics (ATE), Resverlogix (RVX), Aeterna Zentaris (AEZS), Theratechnologies (TH), Oncolytics Biotech (ONC), Medicenna Therapeutics (MDNA), and Sernova (SVA). These companies are all part of the "biotechnology" industry.
Helix BioPharma (TSE:HBP) and Microbix Biosystems (TSE:MBX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings, risk and community ranking.
Microbix Biosystems received 4 more outperform votes than Helix BioPharma when rated by MarketBeat users. Likewise, 70.71% of users gave Microbix Biosystems an outperform vote while only 63.46% of users gave Helix BioPharma an outperform vote.
Helix BioPharma has a beta of -0.74, indicating that its stock price is 174% less volatile than the S&P 500. Comparatively, Microbix Biosystems has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500.
Microbix Biosystems has higher revenue and earnings than Helix BioPharma. Helix BioPharma is trading at a lower price-to-earnings ratio than Microbix Biosystems, indicating that it is currently the more affordable of the two stocks.
Microbix Biosystems has a net margin of 16.57% compared to Helix BioPharma's net margin of 0.00%. Microbix Biosystems' return on equity of 14.66% beat Helix BioPharma's return on equity.
In the previous week, Helix BioPharma and Helix BioPharma both had 1 articles in the media. Helix BioPharma's average media sentiment score of 0.67 beat Microbix Biosystems' score of 0.00 indicating that Helix BioPharma is being referred to more favorably in the media.
0.4% of Microbix Biosystems shares are held by institutional investors. 21.7% of Helix BioPharma shares are held by insiders. Comparatively, 14.1% of Microbix Biosystems shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Microbix Biosystems beats Helix BioPharma on 12 of the 14 factors compared between the two stocks.
Get Helix BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for HBP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Helix BioPharma Competitors List
Related Companies and Tools
